NEW YORK (GenomeWeb News) – Dominion Diagnostics today said that it has licensed rights to genetic testing technology from LifeGen.
The firms are currently collaborating on a study to validate LifeGen's test, which determines a patient's Genetic Addiction Risk Score. The test is being compared in the study to the Addiction Severity Index marketed by Inflexxion.
The LifeGen test includes a panel of genes primarily involved in brain reward circuitry, said North Kingston, RI-based Dominion Diagnostics. The firms, however, didn't provide specific details of which genes are in the panel, but they noted that a subset of the population "carries the DRD2 Type A1 receptor gene, which induces low dopamine brain function that results in the propensity for addictive cravings."
Further details of the alliance and licensing agreement were not disclosed.